Spruce Biosciences, Inc. (SPRB)

Spruce Biosciences, Inc. (SPRB) — VMCI valuation read

The headline on Spruce Biosciences, Inc. (SPRB) is a 39/100 VMCI score, set against a Healthcare sector median of 50. That 11-point below-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value drag is in the data.

SPRB insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.

**Investor frame.** SPRB trades at 17.0x earnings, 6% below the Healthcare median of 18.0x sets the value side. ROIC of 19.0% sits 9.0pp above the Healthcare median (10.0%) sets the quality side. Net debt to EBITDA of 1.1x leaves covenant headroom sets the risk side, the three lines a value buyer reads first on SPRB.

SPRB rose 0.3% over the trailing 7 days, with a -23.9% read on a 30-day basis.